Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | -.--% | +35.54% |
May. 24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
May. 24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
+2.15% | 92.1B | |
-3.16% | 37.92B | |
-12.49% | 32.97B | |
+73.89% | 27.92B | |
-11.82% | 16.14B | |
-0.16% | 14.1B | |
-11.18% | 11.66B | |
+171.57% | 10.29B | |
-50.45% | 9.99B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Shanghai Henlius Biotech's Fibrosis Drug Gets Chinese Authorities' Nod for Clinical Trials